BioSyent Releases 2010 Third Quarter Financial Results-Revised
April 13 2011 - 4:00PM
Marketwired
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) has filed revised
financial statements for the third quarter ending September 30,
2010 to include a certificate that the interim financial statements
have not been reviewed or audited by external auditors. There have
been no changes in the financial statements filed originally on
November 24, 2010.
BioSyent Inc. is a publicly traded specialty pharmaceutical
company whose wholly owned subsidiary, BioSyent Pharma Inc.,
sources, acquires or in-licences pharmaceutical products and
markets these products in Canada. Wholly owned BioSyent subsidiary
Hedley Technologies Ltd. operates the company's legacy business
marketing bio and health friendly non-chemical insecticides.
BioSyent common shares are listed for trading on the TSX Venture
Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that
are forward-looking. The contents herein represent our judgment, as
at the release date, and are subject to risks and uncertainties
that may cause actual results or outcomes to be materially
different from the forward-looking information or statements.
Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX Venture Exchange assumes no responsibility for the
accuracy of this release and neither approves nor disapproves of
the same.
Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905)
206-0013 (905) 206-1413 (FAX) www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024